Sundararajan Vincent Rajkumar

Sundararajan Vincent Rajkumar


Prominent publications by Sundararajan Vincent Rajkumar

KOL Index score: 25909

BACKGROUND: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and ...

Known for 3 Study |  Pomalidomide Dexamethasone |  Refractory Multiple |  Patients Isatuximab |  Monoclonal Antibodies
KOL Index score: 22815

BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma. Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone (KRd), has shown promising efficacy in phase 2 trials and might improve outcomes compared with VRd. We aimed to assess whether the KRd regimen is superior to the VRd regimen in the treatment of newly diagnosed multiple myeloma in patients who were not being ...

Known for Patients Vrd |  Diagnosed Multiple |  Induction Therapy |  Lenalidomide Dexamethasone |  Phase 3
KOL Index score: 21794

BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma ...

Known for Newly Diagnosed Myeloma |  3 Trial |  Dexamethasone Patients |  Swog S0777 |  Bortezomib Lenalidomide
KOL Index score: 16990

BACKGROUND: Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT.

METHODS: The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place ...

Known for Ixazomib Maintenance |  3 Trial |  Cell Transplantation |  Autologous Stem |  Patients Multiple Myeloma
KOL Index score: 16327

BACKGROUND: High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose dexamethasone plus lenalidomide.

METHODS: Patients with untreated symptomatic myeloma were randomly assigned in this open-label non-inferiority trial to lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1-4, 9-12, and 17-20 of a 28-day cycle (high dose), or ...

Known for Dose Dexamethasone |  Initial Therapy |  Multiple Myeloma |  Versus Lenalidomide |  Cycles Patients
KOL Index score: 14785

Translocations involving immunoglobulin (Ig) loci and chromosome 13 monosomy (Delta 13) are frequent cytogenetic findings in multiple myeloma (MM). Similar chromosomal aberrations have been identified in the monoclonal gammopathy of undetermined significance (MGUS), but their prevalence and significance remain uncertain. Bone marrow from 72 patients with MGUS (n = 62) and smoldering MM (n = 10) was evaluated for translocations between the Ig heavy chain (IgH) and chromosomes 4, 11, and ...

Known for Human Pair |  Undetermined Significance |  Mgus Mm |  Fibroblast Growth Factor |  13 Chromosomes
KOL Index score: 14173

BACKGROUND: Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma.

METHODS: Patients in the United States and Canada who had received at least one previous therapy for multiple myeloma but who required additional treatment were randomly assigned to receive either 25 mg of lenalidomide or placebo on days 1 to 21 of a 28-day cycle. Both groups also received 40 mg of ...

Known for Multiple Myeloma |  Lenalidomide Placebo |  North America |  Dexamethasone Patients |  Median Time Progression
KOL Index score: 13868

PURPOSE: To determine if thalidomide plus dexamethasone yields superior response rates compared with dexamethasone alone as induction therapy for newly diagnosed multiple myeloma.

PATIENTS AND METHODS: Patients were randomly assigned to receive thalidomide plus dexamethasone or dexamethasone alone. Patients in arm A received thalidomide 200 mg orally for 4 weeks; dexamethasone was administered at a dose of 40 mg orally on days 1 to 4, 9 to 12, and 17 to 20. Cycles were repeated every 4 ...

Known for Dexamethasone Patients |  Clinical Trial |  Diagnosed Multiple |  4 Weeks |  Phase Iii
KOL Index score: 13586

Angiogenesis or new vessel formation is an essential component in the growth and progression of neoplasms and there is growing evidence of its importance in hematological malignancies including multiple myeloma (MM). Vascular endothelial growth factor (VEGF) is believed to play a role in tumor angiogenesis. We studied the expression of VEGF and its receptors (VEGFR1 or Flt-1 and VEGFR2 or Flk-1/KDR) by myeloma cell lines and plasma cells isolated from patients, using different methods. ...

Known for Myeloma Cells |  Expression Vegf |  Endothelial Growth |  Cell Lines |  Factor Vascular
KOL Index score: 13577

BACKGROUND: Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity.

METHODS: In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients with relapsed myeloma that was refractory to the therapy they had received most recently. Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 weeks, followed by 1 week without ...

Known for Refractory Myeloma |  Response Bortezomib |  Phase 2 |  Drug Drug Therapy |  Combination Female
KOL Index score: 13458

PURPOSE: The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown. The goal of this study was to compare thalidomide plus dexamethasone versus placebo plus dexamethasone (placebo/dex)as primary therapy for newly diagnosed MM.

PATIENTS AND METHODS: In this double-blind, placebo-controlled trial, patients with untreated symptomatic MM were randomized to thal/dex (arm A) or to placebo plus dexamethasone (dex) ...

Known for Thal Dex |  Initial Therapy |  Diagnosed Multiple |  Time Progression |  Cycle Patients
KOL Index score: 12911

We compared the angiogenic potential of bone marrow plasma and the expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and their receptors on plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and newly diagnosed multiple myeloma (NMM). Cytokine and cytokine-receptor expression was studied by bone marrow immunohistochemistry, quantitative reverse transcription-polymerase ...

Known for Bone Marrow |  Angiogenic Cytokines |  Mgus Smm |  Growth Factor |  2 Humans
KOL Index score: 12816

Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting ...

Known for Plasma Exchange |  Cast Nephropathy |  Free Light Chains |  Renal Disease |  Multiple Myeloma Treatment
KOL Index score: 12807

Myeloma kidney is the major cause of severe irreversible renal failure in patients with multiple myeloma. This tubulointerstitial injury is a direct consequence of high concentrations of circulating monoclonal free light chains (FLCs) produced by a clonal expansion of plasma cells. Early reduction of serum FLCs associates with renal recovery, but the target threshold of reduction to facilitate renal recovery is unknown. To determine the relationship between the achieved FLC reduction and ...

Known for Renal Recovery |  Myeloma Kidney |  Light Chains |  Flc Reduction |  Aged 80
KOL Index score: 12662

BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is defined by expression of heavy-chain immunoglobulin (IgH) and is the precursor lesion for 80% of cases of multiple myeloma. The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS.

METHODS: We used a population-based cohort, previously assembled to estimate MGUS prevalence, of 21,463 residents of Olmsted County, MN, USA, ...

Known for Undetermined Significance |  Light Chain |  Risk Progression |  Mgus Prevalence |  Monoclonal Gammopathy


Sundararajan Vincent Rajkumar: Influence Statistics

Sample of concepts for which Sundararajan Vincent Rajkumar is among the top experts in the world.
Concept World rank
mgus firstdegree relatives #1
mgus blood relatives #1
celiac disease negative #1
positive petct #1
amyloidosis rashes #1
mm preceding diagnosis #1
ktx mm #1
standardrisk patients #1
disease definition #1
stage myeloma #1
association mgus #1
cost cancer drugs #1
mm t1114 #1
stemcell collection #1
time point negative #1
grade angiogenesis #1
vegfr1 expression vegfr2 #1
treated thalidomide #1
low dose cycles #1
transplant histologic recurrence #1
nct00558896 #1
crd cybord #1
fish multiple myeloma #1
standard risk patients #1
newly diagnosed myeloma #1
newly diagnosed mm #1
myeloma refractory bortezomib #1
smouldering multiple #1
patients suppression #1
patients median pfs #1
obx protein response #1
dexamethasone thal dex #1
imids initial therapy #1
relatives mgus #1
disease definition staging #1
myc structural variants #1
– dex #1
staging risk stratification #1
thalidomide 200 #1
dex therapy #1
multiple myeloma dex #1
secondary monoclonal #1
stratification multiple #1
choice initial therapy #1
swog1211 #1
proteinuria daratumumab #1
adhesion molecules pcs #1
lenalidomide therapy amyloidosis #1

Key People For Multiple Myeloma

Top KOLs in the world
Kenneth Carl Anderson
multiple myeloma mm cells board directors
Robert A Kyle
multiple myeloma undetermined significance consultancy funding
Sundararajan Vincent Rajkumar
multiple myeloma consultancy funding undetermined significance
Paul Gerard Guy Richardson
multiple myeloma board directors advisory committees
JesusFernando San San Miguel
multiple myeloma consultancy honoraria board directors
Bart Barlogie
multiple myeloma total therapy gene expression

Sundararajan Vincent Rajkumar:Expert Impact

Concepts for whichSundararajan Vincent Rajkumarhas direct influence:Multiple myeloma,  Undetermined significance,  Monoclonal gammopathy,  Initial therapy,  Light chain,  Bone marrow,  Patients multiple myeloma,  Plasma cells.

Sundararajan Vincent Rajkumar:KOL impact

Concepts related to the work of other authors for whichfor which Sundararajan Vincent Rajkumar has influence:Multiple myeloma,  Bone marrow,  Monoclonal gammopathy,  Undetermined significance,  Stem cell,  Poems syndrome,  Mm patients.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Division of Hematology, Mayo Clinic, Rochester, Minnesota, Rochester, MN, USA | Division of Hematology, Mayo Clinic, Rochester, Minnesota. | Mayo Clinic, Rochester, MN; | Division of Hematology, Mayo Clinic, Rochester, MN; | Division of Hematology, M

FREE Custom List